A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Immunogenetics 2015 Jun 5;67(5-6):295-304. Epub 2015 May 5.

Department of Experimental Therapy, L. Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Science, R. Weigl 12, 53-114, Wroclaw, Poland,

T cell activation plays a crucial role in the development of acute graft versus host disease (aGvHD). Cytotoxic T cell antigen-4 (CTLA-4) is a co-inhibitory molecule that negatively regulates T cell activation, differentiation, and proliferation. Single-nucleotide polymorphisms (SNPs) in CTLA-4 gene may affect its function. Inconsistent observations have been reported regarding the associations of CTLA-4 SNPs with complications after hematopoietic stem cell transplantation (HSCT). Moreover, the majority of the observations were focused on the donors' SNPs. Recently, a few studies have shown that recipients' genetic variations in the CTLA-4 gene might influence HSCT results. The aim of our study was to determine the influence of the CTLA-4 gene polymorphisms of the donors and the recipients on the outcome of HSCT. Altogether, 312 donor-recipient pairs were genotyped for the CTLA-4c.49A>G (rs231775) and CT60G>A (rs3087243) SNPs using the TaqMan®SNP Genotyping Assays. In this study, it was shown that the recipients' CT60G>A[GG] genotype, the myeloablative conditioning regimen, and HSCT from an unrelated donor were independent aGvHD risk factors (odds ratio (OR) 2.63, 95% confidence intervals (95% CI) 1.45-4.59, p = 0.001; OR 2.68, 95% CI 1.65-4.07, p = 0.00003; and OR 1.87, 95 % CI 1.02-3.24, p = 0.04, respectively). Moreover, haplotype analysis revealed that possessing allele A in both of the SNPs decreased the risk of aGvHD approximately 1.5-fold (RR 0.69, p = 0.008). Our data suggest that the CT60G>A[GG] genotype in the recipient has an impact on aGvHD development, especially in patients receiving transplants from unrelated donors together with the myeloablative conditioning regimen.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00251-015-0840-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427628PMC
June 2015
10 Reads

Publication Analysis

Top Keywords

ctla-4 gene
16
host disease
8
graft versus
8
versus host
8
cell activation
8
cell transplantation
8
stem cell
8
hematopoietic stem
8
ct60g>a[gg] genotype
8
acute graft
8
myeloablative conditioning
8
conditioning regimen
8
ctla-4
6
cell
5
snps
5
unrelated donor
4
hsct unrelated
4
ctla-4c49a>g rs231775
4
study recipients'
4
recipients' ct60g>a[gg]
4

References

(Supplied by CrossRef)

S Anjos et al.
J Biol Chem 2002

M Azarian et al.
Blood 2007

AL Bayer et al.
Blood 2009

BR Blazar et al.
J Immunol 1996

K Bogunia-Kubik et al.
Arch Immunol Ther Exp (Warsz) 2004

A Bosch-Vizcaya et al.
Biol Blood Marrow Transplant 2012

JW Chien et al.
Blood 2012

DA Chistiakov et al.
Clin Immunol 2006

DA Chistiakov et al.
J Mol Endocrinol 2003

J Daroszewski et al.
Eur J Endocrinol 2009

P Reuver de et al.
Am J Transplant 2003

Similar Publications